MyFinsight
Home
Blog
About
Maturities of investments
$398,464K
(-52.16%↓ Y/Y)
Proceeds from issuance of
shares through...
$7,761K
(-16.40%↓ Y/Y)
Sales of investments
$22,506K
(-66.97%↓ Y/Y)
Net cash (used in)
provided by investing...
$147,719K
(-26.53%↓ Y/Y)
Net cash provided by
financing activities
$5,701K
(73.97%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$1,397K
(-29.16%↓ Y/Y)
Canceled cashflow
$273,251K
Canceled cashflow
$2,060K
Net increase
(decrease) in cash, cash...
-$77,654K
(4.29%↑ Y/Y)
Canceled cashflow
$154,817K
Stock-based compensation
expense
$41,241K
(-38.94%↓ Y/Y)
Accounts payable
$31,554K
(260.68%↑ Y/Y)
Prepaid expenses and
other current assets
-$13,672K
(-267.43%↓ Y/Y)
Accrued expenses
$6,197K
(544.55%↑ Y/Y)
Accrued compensation
$5,866K
(159.42%↑ Y/Y)
Unrealized foreign
exchange loss (gain)
-$5,173K
(-116.00%↓ Y/Y)
Depreciation and
amortization
$3,002K
(-48.55%↓ Y/Y)
Amortization of operating
lease right-of-use...
$2,924K
(-27.41%↓ Y/Y)
Purchases of investments
$268,677K
(-59.51%↓ Y/Y)
Purchases of property and
equipment
$4,319K
(-40.30%↓ Y/Y)
Purchases of
manufacturing facility...
$255K
(-99.13%↓ Y/Y)
Taxes paid related to
the net share...
$2,060K
(-65.71%↓ Y/Y)
Net cash used in
operating activities
-$232,471K
(19.12%↑ Y/Y)
Canceled cashflow
$109,629K
Net loss
-$284,302K
(7.48%↑ Y/Y)
Other assets
$52,949K
(210.90%↑ Y/Y)
Accrued contract
manufacturing expenses
-$2,816K
(-106.52%↓ Y/Y)
Net accretion of
discounts on investments
$1,182K
(-87.43%↓ Y/Y)
Operating lease
liabilities
-$851K
(-105.81%↓ Y/Y)
Back
Back
Cash Flow
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)
source: myfinsight.com